Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Clinical trial NCT07291063 · RECRUITING

Trial details

NCT number: NCT07291063
Sponsor: Shanghai Zhongshan Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Cholangiocarcinoma

Start date: 2024-07-19
Primary completion: 2029-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.